Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive
disease, with early metastasis and a poor prognosis. Until recently, SCLC treatment …

Small-cell lung cancer (SCLC) represents 10–15% of all lung cancers and has a poor
prognosis. Thoracic radiotherapy plays a central role in current SCLC management …

Objective: To assess the clinical outcomes and toxicities of once daily (QD) simultaneous
dose reduction intensity-modulated radiotherapy (SDR-IMRT-QD; SDR-QD) versus …

Small-cell lung cancer (SCLC) accounts for 13% of all lung tumors. The standard treatment
in patients with limited-stage (LS) disease is thoracic radiotherapy (TRT) combined with …

Small cell lung cancer (SCLC) accounts for approximately 20% of all lung cancers. The main
treatment is chemotherapy (Ch). However, the addition of radiotherapy significantly …

Thoracic radiotherapy (TRT) is one of the main treatments in limited-stage small cell lung
cancer (LS-SCLC). Hyperfractionated TRT (45 Gy, 1.5 Gy twice daily) has been the standard …

This thesis is a plea for finding and using biomarkers, to enhance precision medicine in the
treatment of lung cancer patients, and a plea for speeding up the process towards precision …

Simple Summary Limited-stage (LS) small-cell lung cancer (SCLC) is a type of lung cancer
that is confined to one side of the chest without cancer spread elsewhere. The outcomes of …

Many major technical developments have occurred during the last decades in radiotherapy:
our efficacy has improved with less toxicity. Nowadays, it allows us to challenge the role of …